Scott Kopetz on Muck Rack

Scott Kopetz

Houston
As seen in: Color Research & Application, Nature, Gut Journal, Taylor & Francis Online, Medscape, Cell Press, The Lancet, Healio, HemOnc Today, Molecular Cancer Research and
Colorectal cancer physician scientist, NCI Colon Task Force Chair, Professor, and Deputy Chair at The University of Texas, MD Anderson Cancer Center.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Scott

Contact Scott, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Insights from the ASCO Annual Meeting

|
By Scott Kopetz
| Oncology Learning Network
Clinical Summary: Design/Population: Cohort 3 of the phase 3 BREAKWATER trial randomized 147 patients with previously untreated, BRAF V600E-mutant metastatic colorectal cancer and ECOG performance status 0–1 to receive encorafenib plus cetuximab and FOLFIRI (EC+FOLFIRI) or standard FOLFIRI-based therapy with or without bevacizumab.
Open in Who Shared Issue with article?

IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer

|
By Akash R Boda, Irfan N Bandey, Saikat Chowdhury, Sadhna Aggarwal, Venugopalareddy Mekala, Natalie Fowlkes, Amanda Anderson, Jason Roszik, Michael Curran, Van Morris, Scott Kopetz, Manisha Singh 
| Nature
Abstract Pancreatic ductal adenocarcinoma (PDAC) has a poor survival rate and limited treatments. Agonistic CD40 antibodies are promising, but clinical trials have shown only modest efficacy and significant hepatotoxicity. We previously reported that IL-1 pathway blockade enhances CD40 agonist efficacy against melanoma by depleting polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs; CD11b+Ly6C+Ly6G+).
Open in Who Shared Issue with article?

Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures

|
By Nan Deng, Fahriye Duzagac, Ana Bolivar, Laura Reyes-Uribe, Melissa Taggart, Luigi Ricciardiello, Patrick Lynch, Y. Nancy You, Scott Kopetz, Paul Scheet, Gregory Lizée, Alexandre Reuben, Fátima Marín, Marta Pineda, Krishna Sinha, Ajay Bansal, Gabriel Capellá, Eduardo Vilar, Selvi Thirumurthi
| Nature
Abstract Lynch Syndrome (LS) provides the perfect context to understand DNA mismatch repair deficient carcinogenesis, which is characterized by neoplastic lesions with high rates of shared neoantigens eliciting adaptive immunity through T cell receptor (TCR) recognition. However, the TCR landscape in LS carriers remains unexplored. Here, we perform TCR sequencing of 277 blood samples from LS cancer survivors, previvors, and controls, as well as matching colorectal cancers and pre-cancers.
Open in Who Shared Issue with article?
See all 119 licensed articles (135 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Scott

Contact Scott, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified